HIMS
Hims & Hers Health, Inc.
There isn't enough reported data to score HIMS yet.
OMCL
Omnicell, Inc.
OMCL's fundamentals are strong and it looks cheap: trading at 36x earnings, about half its usual 80x. Analysts expect earnings growth, though they disagree widely on how much.
HIMS Fundamentals
| Metric | Status |
|---|---|
| Strong | |
| Weak | |
| Stable | |
| Strong |
HIMS's revenue and balance sheet are currently strong, and its cash flow is stable, but its profitability is weak.
OMCL Fundamentals
| Metric | Status |
|---|---|
| Stable | |
| Healthy | |
| Healthy | |
| Strong |
OMCL's profitability, cash flow and balance sheet are currently healthy, and its revenue is stable.
HIMS PE Valuation
HIMS has no meaningful PE right now: it lost money over the past year.
OMCL PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Forward | 18x | $34.95 | — |
| Current | 36x | $34.95 | — |
| Cheap | 52x | $49.71 | +42% |
| Fair | 79x | $75.94 | +117% |
| Expensive | 153x | $147 | +320% |
Historical ranges are pointers, not guarantees.
OMCL's PE is in its cheap range at 36x. If earnings grow as analysts expect, today's price would be 18x next year's earnings.
HIMS Forward outlook
| Metric | Outlook |
|---|---|
| -- | |
| Turning to a loss | |
| Strong growth | |
| Stable | |
| Limited | |
| Low |
Analysts expect HIMS's revenue to grow, but its earnings to decline. However, they disagree widely on these estimates.
OMCL Forward outlook
| Metric | Outlook |
|---|---|
| Strongly improving | |
| Growth | |
| Stable | |
| Improving | |
| Limited | |
| Low |
Analysts expect OMCL's earnings to grow and its profitability to improve, with its revenue holding steady. However, they disagree widely on these estimates.
HIMS Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q3 2026 | -$0.83 | -257% |
| Q2 2026 | -$0.63 | -180% |
| Q1 2026 | -$0.09 | -113% |
| Q4 2025 | $0.51 | -3.8% |
| Q3 2025 | $0.53 | +20% |
| Q2 2025 | $0.79 | +888% |
| Q1 2025 | $0.68 | +$0.69 |
| Q4 2024 | $0.53 | +$0.64 |
HIMS has swung to a loss: it lost $0.83 per share over the past year, after a profit the year before.
OMCL Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Forward | $1.92 | +100% |
| Q3 2026 | $0.96 | +123% |
| Q2 2026 | $0.84 | +68% |
| Q1 2026 | $0.44 | -4.3% |
| Q4 2025 | $0.04 | -85% |
| Q3 2025 | $0.43 | +$0.82 |
| Q2 2025 | $0.50 | +$0.96 |
| Q1 2025 | $0.46 | +$0.92 |
| Q4 2024 | $0.27 | +$0.72 |
OMCL has the edge over HIMS on earnings quality, reporting a profit while its opponent remains loss making.
HIMS Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $890.4M | +49% |
| Q2 2026 | $753.2M | +38% |
| Q1 2026 | $608.1M | +3.8% |
| Q4 2025 | $617.8M | +28% |
| Q3 2025 | $599M | +49% |
| Q2 2025 | $544.8M | +73% |
| Q1 2025 | $586M | +111% |
| Q4 2024 | $481.1M | +95% |
HIMS has the edge over OMCL on sales, with more consistent year-over-year improvement.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | -7.4% | -9.4 points |
| Q2 2026 | -13% | -18 points |
| Q1 2026 | -13% | -23 points |
| Q4 2025 | 1.5% | -2.4 points |
| Q3 2025 | 2% | -3.6 points |
| Q2 2025 | 4.9% | +1.4 points |
| Q1 2025 | 9.9% | +6.3 points |
| Q4 2024 | 3.9% | +4 points |
HIMS's operating margin was −7.4% last quarter, down 9.4 points from the same quarter a year ago.
OMCL Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $307.9M | -0.9% |
| Q2 2026 | $312.2M | +7.4% |
| Q1 2026 | $309.9M | +15% |
| Q4 2025 | $314M | +2.3% |
| Q3 2025 | $310.6M | +10% |
| Q2 2025 | $290.6M | +5% |
| Q1 2025 | $269.7M | +9.6% |
| Q4 2024 | $306.9M | +19% |
OMCL's revenue is growing: $308M last quarter, about level with the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | 4.8% | +2.2 points |
| Q2 2026 | 10% | +7.6 points |
| Q1 2026 | 5.4% | +9.8 points |
| Q4 2025 | 0.1% | -3.9 points |
| Q3 2025 | 2.6% | +0.3 points |
| Q2 2025 | 2.8% | +1.6 points |
| Q1 2025 | -4.3% | +4.6 points |
| Q4 2024 | 4% | +13 points |
OMCL has the edge over HIMS on profitability, with a higher operating margin.
HIMS Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | $26M | -67% |
| Q2 2026 | -$68.2M | +$1.3M |
| Q1 2026 | $53.1M | +5.9% |
| Q3 2025 | $79.3M | -7% |
| Q2 2025 | -$69.5M | -230% |
| Q1 2025 | $50.1M | +94% |
| Q3 2024 | $85.3M | +238% |
| Q2 2024 | $53.6M | +219% |
HIMS has the edge over OMCL on cash flow, with more consistent year-over-year improvement.
OMCL Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | $21.7M | +17% |
| Q2 2026 | $59.4M | +92% |
| Q1 2026 | $42.1M | +185% |
| Q4 2025 | $22.6M | -52% |
| Q3 2025 | $18.5M | +33% |
| Q2 2025 | $31M | -37% |
| Q1 2025 | $14.8M | -64% |
| Q4 2024 | $47.2M | +61% |
OMCL still generates free cash flow, though less than at its 2020 peak: $146M over the past year.
HIMS Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +0.9% | +2.1M shares |
| 1 year | -6% | -14.9M shares |
| 3 years | +11% | +23.7M shares |
| 5 years | +17% | +33.8M shares |
HIMS has the edge over OMCL on shareholder dilution, with a more favorable share count trend.
| Quarter | Spent |
|---|---|
| Q4 2025 | $80.5M |
| Q3 2025 | $9.5M |
| Q2 2025 | — |
| Q1 2025 | — |
| Q4 2024 | $5M |
| Q3 2024 | $30M |
| Q2 2024 | $19.9M |
| Q1 2024 | $28.1M |
OMCL Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +0.4% | +164K shares |
| 1 year | +1.2% | +566K shares |
| 3 years | +1.9% | +871K shares |
| 5 years | -3.9% | -1.9M shares |
| Available history | +8.2% | +3.5M shares |
OMCL has 46M diluted shares, up 1.2% from a year ago.
| Quarter | Spent |
|---|---|
| Q3 2026 | — |
| Q4 2025 | — |
| Q3 2025 | $61.9M |
| Q4 2023 | — |
| Q3 2023 | — |
| Q2 2023 | — |
| Q1 2023 | — |
| Q4 2022 | — |
HIMS Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q1 2026 | -5.9x | Net Cash |
| Q4 2025 | -1.4x | Net Cash |
| Q3 2025 | -2.2x | Net Cash |
| Q2 2025 | -7.3x | Net Cash |
| Q1 2025 | -2.1x | Net Cash |
| Q4 2024 | -2.8x | Net Cash |
| Q3 2024 | -2.9x | Net Cash |
| Q2 2024 | -5.5x | Net Cash |
HIMS has more cash than debt.
OMCL Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q3 2026 | -1.0x | Net Cash |
| Q2 2026 | -0.9x | Net Cash |
| Q1 2026 | -0.6x | Net Cash |
| Q4 2025 | -0.3x | Net Cash |
| Q3 2025 | -0.1x | Net Cash |
| Q2 2025 | -0.6x | Net Cash |
| Q1 2025 | -0.5x | Net Cash |
| Q4 2024 | -0.3x | Net Cash |
OMCL has more cash than debt.
HIMS Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 36.0 | Neutral |
| Stochastic | 23.0 | Neutral |
HIMS's weekly RSI is 36 (neutral) and its Stochastic is 23 (neutral).
OMCL Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 45.4 | Neutral |
| Stochastic | 46.9 | Neutral |
OMCL's weekly RSI is 45 (neutral) and its Stochastic is 47 (neutral).
HIMS PE vs Healthcare Sector
| Metric | HIMS | Sector median | Relative |
|---|---|---|---|
| PE | N/A | 26x | — |
HIMS has no meaningful PE right now: it lost money over the past year.
OMCL PE vs Healthcare Sector
| Metric | OMCL | Sector median | Relative |
|---|---|---|---|
| PE | 36x | 26x | 41% above |
| PE % | 0 | 29 | 29 pts below |
OMCL is trading at 36x earnings, a 41% premium to the Healthcare sector's median of 26x.
HIMS Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $27.3 | 28% below |
| 20 week MA | $29.2 | 32% below |
| 50 week MA | $27.7 | 29% below |
| 100 week MA | $35.9 | 45% below |
| 200 week MA | $24.4 | 19% below |
HIMS is in a downtrend: it's below all five of its weekly moving averages, and 19% below its 200-week average.
OMCL Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $35.7 | 2% below |
| 20 week MA | $36.9 | 5.2% below |
| 50 week MA | $39.6 | 12% below |
| 100 week MA | $36.7 | 4.7% below |
| 200 week MA | $40.9 | 15% below |
OMCL is in a downtrend: it's below all five of its weekly moving averages, and 15% below its 200-week average.
HIMS Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $9.89 | $15.0 | +51% |
| 2021 | $15.0 | $6.65 | -56% |
| 2022 | $6.65 | $6.43 | -3.3% |
| 2023 | $6.43 | $8.90 | +38% |
| 2024 | $8.90 | $26.6 | +198% |
| 2025 | $26.6 | $34.3 | +29% |
| 2026 YTD | $34.3 | $19.7 | -42% |
HIMS's yearly returns have swung widely, from +198% in 2024 to −56% in 2021. It's down 42% so far in 2026.
OMCL Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $82.5 | $118.2 | +43% |
| 2021 | $118.2 | $175.7 | +49% |
| 2022 | $175.7 | $48.4 | -72% |
| 2023 | $48.4 | $37.6 | -22% |
| 2024 | $37.6 | $44.1 | +17% |
| 2025 | $44.1 | $46.4 | +5.3% |
| 2026 YTD | $46.4 | $35.0 | -25% |
OMCL has the edge over HIMS on returns for 2026, with the stronger performance.